Innovations in Drug Pricing and Reimbursement (2016) - New Market Research Report

Is the drug pricing bubble about to burst?

Drug costs are becoming unaffordable and draconian cost containment strategies are being employed.

The pharma industry is winning few friends when it comes to drug pricing. Public, health professional, political and payer hostility is growing worldwide as the prices of new drugs for chronic disease, specialty medicines and even generics grow excessively. How are payers in the US and Europe responding and what cost containment strategies are being - and could be - employed to cap rampant and increasingly unaffordable drug bills?

The pharma industry is winning few friends when it comes to drug pricing. Public, health professional, political and payer hostility is growing worldwide as the prices of new drugs for chronic disease, specialty medicines and even generics grow excessively. How are payers in the US and Europe responding and what cost containment strategies are being - and could be - employed to cap rampant and increasingly unaffordable drug bills?

Full Report Details at
- http://www.fastmr.com/prod/1152025_innovations_drug_pricing.aspx?afid=301

"It's pretty discouraging, unfortunately. It makes you think these companies are not really involved in healthcare. I don't think they are... They just are profit centres." US Payer

Answering key questions:

* A Fundamental Driver: Why, and to what extent, is the pharma industry's focus on orphan diseases and high-end biologics creating such an issue for payers?
* The End of the Wild West? Freeing Medicare to negotiate drug pricing and PBMs utlilising competitive pressures to lower costs are just some of the solutions to controlling US drug prices- what else is on the table and how extreme might regulators get?
* European Variance: Reference pricing, price-volume agreements, tendering, early benefit assessments, HTA cost/benefits assessments, risk-sharing and whole system product value are all being employed - but where and with what success?
* Stakeholder Buy-In: Why, and how, might early and open dialogue between industry and payers benefit both parties?
* Positive Message? Why is industry failing to get its societal and cost-benefit message heard, and what more could it do to win support?
* Same Old, Same Old: In the face of solid profits does industry's narrative of justifying high drug prices to fund innovation and development need an overhaul?
* Risk Sharing: Are risk-sharing, value-based pricing and pricing by indication the best schemes moving forward?
* Local Market, Local Problems: Each country has gone its own way in controlling cost - what could they learn from each other and is drug pricing now a regional rather than just a national issue?
* ...

With this report you will be able to:

* Understand the fundamental research trends that are driving payer concerns and disquiet
* Learn which reimbursement strategies are being employed

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Pay-for-Performance and Drug Pricing: Impact and Response of Pharma [2016]
- Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets
- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Indonesia
- Estonia Pharmaceuticals & Healthcare Report Q2 2016
- Czech Republic Pharmaceuticals & Healthcare Report Q2 2016